June 24, 2023New England Journal of Medicine492 citationsOpen Access
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
View Full Paper
Key Points
- To assess the efficacy and safety of the FGF21 analogue pegozafermin in patients with nonalcoholic steatohepatitis (NASH).
- Conducted a randomized, controlled phase 2b clinical trial (ENLIVEN; ClinicalTrials.gov number, NCT04929483) evaluating pegozafermin treatment.
- Treatment with pegozafermin resulted in improvements in fibrosis (numerical event rates, effect sizes, and p-values not reported in abstract).
- The observed therapeutic improvements support advancing pegozafermin into phase 3 clinical evaluation.
Abstract
In this phase 2b trial, treatment with pegozafermin led to improvements in fibrosis. These results support the advancement of pegozafermin into phase 3 development. (Funded by 89bio; ENLIVEN ClinicalTrials.gov number, NCT04929483.).
Cite This Study
Loomba et al. (2023) studied this question.